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ABSTRACT  
A number of systems based on synthetic molecules, among them cationic liposomes and 
poly(ethylene imine)-based polymers, have been proposed as delivery vehicles for nucleic acids. 
Some of these systems have even reached the market, ensuring efficient and transient transfection 
levels in a variety of cell types. However, toxicity issues have limited their application in vivo. In this 
context, chitosan, a biocompatible and biodegradable polysaccharide, has been proposed as a 
promising alternative for the delivery of nucleic acid-based molecules. Here we present an overview 
of the state of the art of chitosan-based vectors for nucleic acid delivery and the most recent data on 
the in vivo testing of the proposed systems. We additionally express our view on the barriers that 
might be hampering the translation of this knowledge into clinical practice and the challenges that 
need to be fulfilled for these promising vehicles to reach patients. 
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Chitosan: Sources and properties 
Chitosan is a linear co-polymer of D-glucosamine and N -acetyl- D-glucosamine in a β-(1–4) linkage, 
in which glucosamine is the predominant repeating unit (Figure 1). The molar fraction of N-acetylated 
units defines the degree of acetylation (DA) of a given chitosan, expressed in molar percentage of N-
acetylated units. Chitosan is soluble in lightly acidic aqueous solutions. At a pH lower than its pKa, 
ranging from ∼6.5 to ∼7, chitosan is a polycation, and at pH 4.0 and below, it is completely 
protonated.1 The cationic character of chitosan under mildly acidic conditions and its ability to 
complex and condense nucleic acid-based molecules are the basis for its use as a transfection agent. 
Chitosan is mostly obtained by deacetylation of chitin. The most commonly used sources of chitin 
are the exoskeleton of crustaceans and squids. The chitin present in squid pens is easier to 
deacetylate due to the absence of inter-sheet hydrogen bonding.2 To conduct the deacetylation 
process with chitin from crustaceans, harsher conditions need to be applied, and the resulting 
chitosan typically has lower molecular weight. Consequently, this has been the preferred source of 
chitosan for use in nucleic acid delivery, as smaller and less disperse complexes can be formed when 
chitosan of lower molecular weight is used.3,4 In either case, the fact that chitosan has an animal origin 
has raised some concerns, as it might be a potential source of allergens. More recently, chitosan 
isolated from the cell walls of mushrooms has become commercially available. As compared to 
chitosan obtained from marine animal resources, chitosan isolated from fungi cultured under 
controlled growing conditions presents higher reproducibility among batches and traceability,5 
which makes it of interest for application in medical and pharmaceutical products. Irrespective of the 
original source, chitosan of ultrapure grade can now be obtained. 
In addition to its ability to condense nucleic acid-based molecules and protect them from 
endonuclease degradation, a particular advantage of chitosan over other polycations proposed as 
non-viral vectors for nucleic acids relies on its low cytotoxicity and biodegradability. Besides chemical 
hydrolysis, enzymes can also mediate chitosan degradation in vivo.6 Among these, lysozyme has 
been identifi ed as the main one being involved in this process.7,8 It can hydrolyze partially N-
acetylated chitosans, with the active site of the enzyme binding six sugar rings, being three 
consecutive N -acetyl-D-glucosamine residues required for lysozyme catalytic activity.7 As a 
consequence, the susceptibility of chitosan to lysozyme depolymerization depends not only on the 
DA  but also on the distribution of N-acetylated units along the chitosan chains. 
Further contributions to the fi eld are expected when enzymatic production of chitosan will become 
readily available.9 This will allow precise control over the resulting chain molecular weight, DA, and 
the distribution of the monomer units along the polymer backbone. Consequently, nanocomplex 
formation reproducibility and fine-tuning of biodegradation can be achieved, ultimately affecting the 
overall process of cell transfection. 
Chitosan as a vector for nucleic acid delivery 
Gene therapy is currently considered a strategy that provides cells with the genetic information 
required to produce specific therapeutic proteins or increase their overall expression levels, thus 
correcting or modulating specific pathologies. Moreover, the concept has been expanded to include 
specific regulation of gene expression through the use of short oligonucleotides targeting DNA or 
RNA, otherwise named as antisense gene therapy or oligonucleotide gene therapy.  
 Version: Postprint (identical content as published paper) This is a self-archived document from i3S – Instituto de 
Investigação e Inovação em Saúde in the University of Porto Open Repository For Open Access to more of our 
publications, please visit http://repositorio-aberto.up.pt/  
 
A
0
1
/0
0
 
Over the past several years, many attempts have been made to design non-viral vectors that could 
achieve the level of gene expression and specificity attained by viral vectors, while providing greater 
flexibility in terms of size of the transported nucleotide cargo, bypassing the immune system, and 
reducing safety concerns.10 Among them, chitosan-based carriers have gained a great deal of 
attention for delivery of plasmid DNA (pDNA), small interference RNA (siRNA), and single-stranded 
oligonucleotides (ssON) (Figure 2). In the following sections, we present the state of the art of 
chitosan-based nanocarriers, focusing on their ability to deliver different types of nucleic acids. 
Plasmid DNA 
At the molecular level, pDNA can be considered to be a pro-drug that, upon cellular internalization 
and nuclear entry, leads to the biosynthesis of a therapeutic protein11 (Figure 2a). In addition to 
disease treatment, plasmids can be used as DNA vaccines for genetic immunization. DNA vaccines 
function through induction of immune response by introducing gene encoding antigens for specific 
pathogens.12 pDNA is a double-stranded DNA molecule (1–200,000 base pairs) that can occur in three 
topological forms: the compact supercoiled form, the open circular form, and the linearized form. 
Supercoiling arises from inherent properties of the DNA double helix to twist (turn) and writhe (turn 
over itself) and allows formation of a more compact molecule with implications for complex 
formation and transfection capabilities, also dependent on the type of vector used.13 The US Food 
and Drug Administration (FDA) guidelines require the majority of pDNA (>80%) to be in its 
supercoiled form for application in pDNA vaccines for infectious disease indications.14 
There are a large number of reports describing the potential of chitosan and its derivatives for pDNA 
delivery.15 Both chitosan-pDNA complexes16 and chitosan-based nanocarriers prepared by ionic 
gelation17,18 have been described for pDNA transfection. Overall, results revealed that transfection 
efficiency of chitosan-based delivery vehicles is dependent on several formulation parameters, such 
as chitosan molecular weight, DA, and stoichiometry (N / P ratio, moles of positive charges from 
amino groups to moles of negative charges from phosphate groups), among others.19 Therefore, 
these parameters should be carefully considered and optimized when designing a pDNA delivery 
system. An in-depth review describing factors affecting pDNA delivery mediated by chitosan has 
been recently published.20 
Although chitosan has been proposed as an alternative to other non-viral vectors such as cationic 
liposomes or poly(ethylene imine) (PEI), it generally presents lower transfection efficiencies.21 This 
difference could be attributed to its limited solubility at physiological pH as well as to its inefficient 
cellular uptake, endolysosome escape, and polyplex dissociation (see Figure 2a). Consequently, 
several efforts are being made toward improving chitosan transfection efficiency by introducing 
different types of chemical modifi cations into the polymer backbone. 
One common approach to enhance transfection efficiency is by improving chitosan solubility under 
physiological conditions. Chitosan grafted with PEI led to increased solubility, as well as improved 
transfection efficiency in relation to PEI alone.22 Another strategy relies on the grafting of the 
poly(ethylene glycol) chain (PEGylation) to chitosan, which improves polymer solubility, yielding 
nanostructures that are more stable in the blood stream (extending their circulation time) and 
mediating transfection more efficiently.23,24 The quaternization of chitosan by methylation of 
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primary amine groups was also found to improve chitosan solubility and polyplex stability in 
physiological conditions.25 
In order to overcome the endosomal barrier (see Figure 2a),conjugation of imidazole to chitosan has 
been explored to improve chitosan buffering capacity and endosomal escape.26,27 The introduction 
of hydrophobic moieties into the polymer backbone also led to more efficient endosomal escape28 
along with improvement of pDNA condensation capacity due to enhanced interaction between 
tethered hydrophobic domains and nucleic acids. Thiolation of chitosan also resulted in improvement 
of pDNA protection against degradation and formation of more stable complexes via establishment 
of disulfide bonds between chitosan chains. Additionally, in the reductive environment of the 
cytoplasm, there is an enhanced dissociation of pDNA from the polymer resulting in enhanced 
transgene expression.29, 30 Finally, an amphiphilic modification of chitosan has also been attempted. 
Hydrophobic modification of chitosan with linoleic acid led to improved endonuclease protection 
ability, promoting cell binding and enhanced pDNA dissociation. Contrarily, introduction of 
poly(beta-malic acid) via ester bonds led to enhanced water solubility, minimized nonspecific protein 
adsorption, and facilitated pDNA unloading, resulting in an overall improved transfection efficiency.31 
As an alternative to chitosan backbone modification, the preparation of ionically cross-linked 
chitosan-TPP (tripolyphosphate) nanoparticles was also proposed.32 Such systems were found to 
improve stability, achieving comparable gene expression levels to other efficient transfection agents. 
A more advanced system combines chitosan, TPP, and an additional poly/oligosaccharide such as 
hyaluronic acid33 or beta-cyclodextrins.34 
While non-viral vectors can associate with most cell types via nonspecific binding to the cell surface, 
specific targeting strategies based on receptor-ligand interactions are preferable to prevent 
widespread delivery and off-target effects. The incorporation of targeting moieties into the chitosan 
nanoparticles was found to modify the particle uptake, with the ligand/ receptor interaction 
governing the internalization pathway and the subsequent intracellular trafficking.29 , 35 , 36 
Small interfering RNA 
siRNAs are short, usually 19–21 base pair double-stranded synthetic RNA molecules, which elicit the 
degradation of messenger RNA (mRNA), thereby achieving down-regulation of a target gene 
through the mechanism of RNA interference (Figure 2b).37 
Due to its chemical nature, siRNA is highly sensitive to degradation by nucleases and unable to cross 
cellular membranes. Being much smaller than pDNA, siRNA has far less charge 
density, possessing an inherently different structure and topology. These differences underlie the 
specificity of certain synthetic vectors in achieving efficient delivery with only one type of nucleic acid 
molecule. Chitosan-based vectors follow this rule, hence chemical and physical parameters need to 
be  specifically optimized for siRNA delivery. 
To the best of our knowledge, the first report on the use of chitosan-based nanoparticles for siRNA 
delivery was published in 2006.38 This study explored different methods of complexation (simple 
coacervation, ionic gelation, and adsorption to chitosan-TPP nanoparticles prepared by ionic 
gelation) using high molecular weight chitosans (110–470 kDa). The results showed that the 
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molecular weight did not significantly influence transfection efficiency, although smaller particles 
were formed with the lowest molecular weight chitosan. The method of siRNA association, in turn, 
was relevant for transfection efficiency, with entrapment by ionic gelation being the most effective. 
Recent reports highlight the effect of chitosan molecular weight on its interaction with siRNA and 
the transfection efficiency of the resulting complexes. However, the results are not definite yet. Some 
authors indicated that low molecular weight chitosan is not able to stably interact with siRNA merely 
because of insufficient electrostatic interactions between the two oppositely charged molecules. This 
effect was observed when 10 kDa chitosan (5% DA)39  was compared to that of 35 kDa (fully 
deacetylated).40 In contrast, another paper showed that effi cient silencing could be achieved with a 
chitosan of 12 kDa (8% DA).41 
Overall, the conclusion at this point could be that increasing polymer molecular weight might not 
translate into further increases in performance.40,42 This could be explained by a productive 
interaction threshold between siRNA and the polymer chains, leading to sufficient condensation and 
intracellular dissociation capacity of the complexes. The previously mentioned examples also reveal 
that low DAs favor the interaction with siRNA and the overall vector performance. The use of chitosan 
with low DA is particularly crucial when preparing nanoparticles using the ionic complexation 
technique. In contrast, when using the ionic gelation technique, siRNA molecules, besides 
establishing possible ionic interactions with chitosan, are physically entrapped during the particle 
formation process.32,43 
A myriad of modifications in the polymer backbone, aimed at improving nanoparticle formation with 
siRNAs, have been explored. Similar to pDNA delivery, chitosan quaternization44 and chitosan 
thiolation45 have also been investigated. Hydrophobic modification of chitosan with tocopheryl 
(vitamin E) has also been achieved.46 Other possible modifications include glycolchitosan, PEGylated 
chitosan, and guanidinylated chitosan, which have basically conferred improved stability, solubility, 
and cellular uptake resulting in enhanced transfection capabilities.47 Another alternative for efficient 
encapsulation of siRNA combines PEGylated chitosan with hyaluronic acid and the process of 
nanoparticle formation induced by ionic gelation using TPP.48 
Single-stranded oligonucleotides 
The therapeutic potential of single-stranded ONs (ssONs) was discovered in 1978, when Zamecnik 
and Stephenson reported that a DNA oligonucleotide complementary to the target RNA was able to 
inhibit virus replication in cell culture.49 Soon after, the idea of achieving generalized blocking of RNA 
function through hybridization of ssONs with the RNA started to develop and with it the fi eld of 
antisense oligonucleotides (AON). As with siRNAs, these molecules can be easily degraded and have 
difficulty entering cells. Attempts have been made to increase their stability by chemical modification 
and to maintain their effectiveness upon in vivo administration; however, the high amounts of ssONs 
needed to achieve a good response and the lack of specific cell targeting may raise some toxicity 
issues.50 Thus, the development of appropriate delivery vectors is also critical in this context (Figure 
2c). As in the case of siRNA, the small size and low charge density of the molecule poses a problem 
for complexation. Additionally, its single-stranded character confers a slight apolar characteristic to 
the molecule due to exposure of aromatic nitrogenous bases. 
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Although the number of reports on chitosan-based vectors for ssON delivery is still low, there are 
some approaches that have led to promising data. Chitosan nanocomplexes showed transfection 
activity in a model of intranasal application, even though very high amounts (100 μ g) were needed 
to achieve a response.51 In another example, complexes of ssON with a galactose-modified chitosan 
resulted in an improved in vitro transfection efficiency as compared to the parent chitosan 
complexes.52 Moreover, in vivo galactosylation of chitosan was found to vectorize high amounts of 
AON to specific liver cells, which was seen as the major event leading to the increased efficiency of 
this vector.  
The combination of chitosan with alginate for complexation of AON either by a lyophilization 53 or a 
pre-gelling method54 has also led to interesting results. Indeed, chitosan-alginate nanoparticles 
prepared by lyophilization showed a capacity to transfect skin cells in vivo in an excisional wound 
model. Those prepared according to the pre-gelling method were found to control the AON release 
over a 50-hour period55 and to transfect a human breast cancer cell line.56 
The delivery of AON from nanoparticles made by ionic gelation has also been reported in few 
studies.57 A relevant example is the one showing that chitosan nanoparticles are useful carriers of 
AON for delivery into rat skin cells,58 with the authors suggesting the potential of this approach for 
topical application on human skin. More recently, the use of thiolated chitosan in order to facilitate 
the dissociation of the AON from the complex was also explored.59 
Overall, the information reported so far does not yet offer a comprehensive view of the most 
favorable properties for ssON delivery by chitosan. Considering the enormous potential for ssON-
based therapeutics, a more detailed view on the use of chitosan with ssON is warranted. 
In vivo application of chitosan as a vector for nucleic acid delivery 
Since initial proposals of chitosan as a nucleic acid delivery system, chitosan and its derivatives have 
been widely tested as nucleic acid carriers in animal models. The majority of the reported in vivo 
studies focus on the use of reporter gene models in order to evaluate biodistribution and transfection 
levels mediated by chitosan-pDNA complexes.20 Following these pioneering studies, there has been 
an increasing number of reports evaluating the efficacy of chitosan as a delivery carrier of therapeutic 
genes, namely in the fields of cancer, infections, and inflammatory diseases (Table I). 
Due to their mucoadhesive properties, chitosan-based nanoparticles have been applied in the 
development of strategies to treat diseases that affect mucosal surfaces, such as the gastrointestinal 
tract, lung, and eye. Kai and Ochiya reported successful oral delivery of the β -galactosidase reporter 
gene mediated by chitosan alone or N-acetylated to the intestine.60 Others have reported similar 
findings in the gastric and intestinal mucosa. pDNA-loaded chitosan-based nanoparticles have also 
been explored in the fi eld of respiratory diseases. An example is the work of Jiang et al., in which it 
was shown that aerosol delivery of pDNA producing small hairpin RNA, complexed to folate-
chitosan-graft-PEI, specifically silenced the isoform 1 of the protein kinase B (Akt1) in lung tumor 
cells, resulting in lung tumorogenesis suppression.61  
Hyaluronic-chitosan nanoparticles made by ionic gelation have also been proposed for the delivery 
of nucleic acids to the ocular mucosa, which is a thin, continuous mucous membrane layer that lines 
the inner surface of the eyelids and eye surface.62,63 In this case, the mucoadhesive properties of both 
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polymers were combined with the CD44 targeting ability of hyaluronic acid, rendering the system 
very efficient for transfection of both the corneal epithelium and conjunctiva, ocular tissues that 
express this receptor.  
Another field of application has been mucosal administration of vaccines. For example, Roy et al. 
reported that oral immunization with pDNA vaccine-loaded chitosan nanoparticles led to successful 
immunological protection in a murine peanut allergy model.64 Another pDNA vaccine encoding for 
the dense granule protein 1 (GRA1) has been proposed, intended to prevent Toxoplasma gondii 
infection. A significant immune response against the encoded protein was observed after gastric 
administration of chitosan nanoparticles containing GRA1 pDNA to mice.65 Nanovaccines have also 
been designed for intranasal administration. For example, a pDNA-loaded chitosan nanoparticle 
vaccine against the respiratory syncytial virus (RSV) infection was developed and tested in a murine 
model. The results showed an attenuation of pulmonary inflammation by induction of protective T 
helper 1 (Th1) cell type66 and cytotoxic T lymphocyte responses 67 in BALB/c mouse strain. 
The encouraging results of chitosan in delivering pDNA molecules drove interest in it as an attractive 
carrier for siRNA. Compared to in vivo pDNA delivery, research on siRNA delivery mediated by 
chitosan-based vectors is still in its infancy, the majority of current work being basic research 
involving model siRNA molecules. Delivery of siRNA for therapeutic purposes has recently started to 
receive increasing attention, with specific emphasis in the field of infectious diseases and cancer 
(Table I). One example is intranasal delivery of chitosan nanoparticles loaded with siRNA targeting 
the viral NS1 gene that encodes for a RSV nonstructural protein sequence with an important role in 
the virus replication process. The results showed a significant reduction of virus concentration (titers) 
in the lung and decreased pulmonary inflammation associated with RSV infection.68,69 On the other 
hand, in the field of cancer therapy, Pille et al. reported a 90% inhibition of tumor growth in a 
xenograft aggressive breast cancer model after intravenous administration of anti–Ras homologous 
A (Rho A) siRNA encapsulated in chitosan-coated polyisohexylcyanoacrylate nanoparticles.70 
 Although being reported as one of the most promising nucleic acid carriers for clinical applications, 
so far chitosan-based nanoparticles have only been evaluated in pre-clinical settings. Therefore, 
much research is needed in order to advance toward the clinical development phase. This 
advancement is expected to be favored by the fact that several chitosan-based products are under 
clinical development, among them, an adjuvant for a Norwalk virus-like particle, 71 whereas others, 
such as for wound dressing and as a dietary supplement, are already being marketed.71- 73  
Translating chitosan into the clinic for nucleic acid delivery: 
progress and challenges 
The use of chitosan nanocarriers for gene therapy is largely documented, and there is now a 
considerable body of knowledge supporting this application. Notwithstanding, there are still no 
reports of marketed products or current clinical trials with chitosan-based vectors for in vivo 
administration of nucleic acids. While trying to bring such products from bench-to-bedside, a number 
of requisites must be taken into account. Important issues to be tackled are inherent to the use of 
nucleic acids as therapeutic molecules, namely the optimization of sequences to ensure robust gene 
expression while evading immune system surveillance (pDNA) or to minimize off-targets and reduce 
toxicity effects (ssONs and siRNA), as well as to determine therapeutic dosages. On the other hand, 
the proposed vector needs to fulfill its role as a carrier of the therapeutic agent. Some of the 
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strategies being pursued to improve the efficiency of chitosan for nucleic acid delivery have been 
discussed in the previous sections. Most of the chitosan-related limitations are common to other 
vectors, as well as approaches being adopted to overcome these hurdles. 
It is also important to consider that while chitosan is not currently listed as an excipient in any drug 
formulation approved by regulatory authorities, chitosan hydrochloride has been on the list of 
excipients of the European Pharmacopeia since 2002 92 and in the US Pharmacopeia and The National 
Formulary since 2011.93 Moreover, chitosan (from shrimp and Aspergillus niger origin) is “generally 
recognized as safe” by the FDA as a direct ingredient in foods and beverages.94 Chitosan is also being 
used as a dietary supplement to reduce fat adsorption and in wound dressings,95 indicating that a 
good understanding of its topical and oral tolerance exists. In addition, there are a number of clinical 
trials reported by the FDA involving the use of chitosan for oral and nasal peptide/vaccine delivery 
where chitosan is being used as a vaccine adjuvant. In spite of this, there is still a need for standard 
guidelines describing the range of requirements, both for suppliers and product manufactures, of 
product quality and characterization methods.96 The American Society for Testing and Materials 
(ASTM) is making a concerted effort to establish standard guidelines for tissue-engineered medical 
products and has recently dedicated one of these documents (F2103–11) to the characterization and 
testing of chitosan salts as starting materials for biomedical applications.97 
One must be aware that chitosan is not a single chemical entity but varies in compositional DA and 
distribution of the monomer units along the polymer backbone and molecular weight, depending on 
the source, extraction, and preparation method.96, 98, 99 For nucleic acid delivery, the polymer 
molecular weight and DA are very important parameters, as they will have an impact in terms of chain 
flexibility and the number of positive charges per chitosan molecule. Moreover, solubility, 
biodegradability, aggregation properties, and immune response will be affected by physicochemical 
properties of chitosan as well.100 In this context, regulatory issues concerning polymer preparation 
and characterization methods will have to be addressed such that chitosan can successfully reach the 
clinic. In this respect, there are three main areas that must be dealt with: (1) polymer characterization 
and functionality, (2) product reproducibility between different batches, and (3) toxicology and long-
term safety.101  
The ASTM guideline F2103–11 suggests the use of infrared spectroscopy (IR) and nuclear magnetic 
resonance (NMR) to correctly identify chitosan.97 It also establishes limits of insoluble impurities, 
residual protein content, inorganic matter, and presence of heavy metals in the chitosan samples. 
The ASTM standard F2260–03 describes the methodology for determination of chitosan DA using 
1H-NMR.102 It is based on the work of Vårum et al. and is valid for DA values from 50% down to 1%.103 
For molecular weight determination, a specific ASTM standard (F2602–08E011) has been 
published.104 Several mobile phases are proposed for size exclusion chromatography, with many 
composed of not only acetic acid and sodium acetate, but also ammonium acetate. Finally, according 
to FDA specifi cations, the endotoxin content of chitosan samples should not exceed 5 EU/kg for non-
intrathecal administration routes, in order for the material to be considered safe for biomedical 
applications.105  
The ASTM guidelines represent a promising attempt to surpass some of the diffi culties listed 
previously. If properly followed, they should improve the manufacturing efficiency of chitosan-based 
products, with significant reduction in the cost of product development.  
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Another key issue to take into consideration is chitosan biodegradability. In the literature, multiple 
studies regarding chitosan processed in different forms (hydrogels, scaffolds, beads, or just in 
solution) have asserted this material as biodegradable. Most of these studies assess biodegradation 
upon variation of the polymer DA, since this parameter is positively related with the rate of chitosan 
degradation. In spite of this, little is known about the degradation of chitosan in nanoparticle 
systems.106 The extrapolation to nanoparticle biodegradation is not straightforward, because when 
the polymer is complexed with nucleic acids, the exposure of acetylated groups may not favor the 
degradation 
mediated by enzymes. Chellat and colleagues evaluated biodegradation of chitosan and chitosan 
complexed with xanthan (CH-X) (an anionic polysaccharide) in degradation media simulating gastric 
(containing pepsin) or intestinal fluids (containing pancreatin) and found that chitosan degradation 
was faster than CH-X microspheres.107 To the best of our knowledge, in vivo degradation of chitosan 
nanoparticles containing nucleic acids has not been disclosed in the literature. It is worthwhile 
mentioning that this is a common limitation for most nanoparticulate systems. 
Conclusions 
This review highlights some of the most promising results involving the use of chitosan as a vector 
for nucleic acids, including examples already in pre-clinical trials that have been fueling the interest 
of the research community and manufacturers into use of this biopolymer. Chitosan has advantages 
over other non-viral carriers in terms of its nontoxicity and biodegradability. Another interesting 
feature widely explored is the mucoadhesive properties of chitosan, with impact on gastrointestinal, 
lung, and ocular applications. 
While the field of gene therapy is still addressing many of the hurdles that have been hampering the 
widespread translation of nucleic acid-based therapies to the clinic, there are several products in 
clinical trials based on both viral and non-viral vectors supporting the high potential of such 
therapeutic strategies. Recently, two products successfully reached the market (Glybera and 
Gendicine) for the treatment of lipoprotein lipase deficiency and head and neck squamous cell 
carcinoma, respectively. Nevertheless, attaining safe and efficient delivery of the nucleic acid of 
interest is at the forefront of this quest, which makes chitosan and its derivatives attractive 
candidates. 
While a number of issues that are common to all non-viral vectors remain to be addressed, there are 
a number of questions that are particular to chitosan. Many of these involve standardization of 
production and characterization methodology. While seemingly trivial, these issues have held back 
manufacturers and made comparison between studies difficult at times. Addressing these issues will 
certainly provide the basis for a deeper understanding of the behavior of this material in different 
biomedical settings, of which vectorization of nucleic acids is an example with great therapeutic 
potential. We believe that this will make pharmaceutical companies more secure to bring chitosan 
into clinical trials and finally to the market. 
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Figure 1. Chemical structure of partially deacetylated chitosan. a: D-glucosamine; b: N -acetyl D-
glucosamine. Note: n , repetition unit. 
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Glossary 
Alginate: Anionic polysaccharide present in the cell wall of brown algae. 
Chitin: A high molecular weight, crystalline polysaccharide, theoretically composed entirely of N-
acetylglucosamine units; it is the main component of the cell walls of fungi, the exoskeletons of 
arthropods such as crustaceans (e.g., crabs, lobsters, and shrimps) and insects, as well as it is present 
in the endoskeleton of cephalopods, including squid and octopuses. 
Coacervation: The process that results in the aggregation of molecules or formation of colloidal 
particles under the action of electrostatic attractive forces. 
Ionic gelation: The process of formation of particles driven by the reticulation (gelation) of a polymer 
induced by small charged molecules. 
Endonuclease: Phosphodiesterase that cleaves bonds within a polynucleotide chain. 
Endotoxin: Toxin present inside a bacterial cell that is released when it disintegrates; consists of 
lipopolysaccharide and lipoprotein complexes. 
Intrathecal administration: Administration of a therapeutic agent into the subarachnoid space, which 
contains the cerebrospinal fl uid, in the spinal cord. 
pKa: Decimal logarithm of the acid dissociation constant. 
Polyplex: Complex between the cationic polymer and anionic nucleic acid. 
Pro-drug: Therapeutic agent administered in an inactive form that must undergo a chemical or 
biological conversion before becoming an active agent. 
Transfection: the process of deliberately introducing nucleic acids into cells. 
 
 
